Using Osteoporosis Therapies in Combination

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis

(2017) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis

(2017) Felicia Cosman et al.   MAYO CLINIC PROCEEDINGS

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics

(2016) Erik Fink Eriksen et al.   BONE

Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment

(2016) Astrid Fahrleitner-Pammer et al.   BONE

Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study

(2016) David W Dempster et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis

(2016) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)

(2016) J. N. Tsai et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

(2016) P. D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

(2016) Felicia Cosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancel the denosumab holiday

(2016) M. R. McClung   OSTEOPOROSIS INTERNATIONAL

Teriparatide and denosumab combination therapy and skeletal metabolism

(2016) L. Idolazzi et al.   OSTEOPOROSIS INTERNATIONAL

Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity

(2015) Ego Seeman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2015) Dennis M. Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface?

(2015) Natalie A. Sims et al.   Frontiers in Endocrinology

Overlapping and Continued Alendronate or Raloxifene Administration in Patients on Teriparatide: Effects on Areal and Volumetric Bone Mineral Density-The CONFORS Study

(2014) Christian Muschitz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study

(2014) Joy N Tsai et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial

(2014) Benjamin Z. Leder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches

(2014) Felicia Cosman   Current Osteoporosis Reports

Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment

(2013) Yanfei L. Ma et al.   BONE

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

(2013) C. Roux et al.   BONE

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

(2013) Joy N Tsai et al.   LANCET

Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women

(2013) Yong-Ki Min et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy

(2013) Chris Recknor et al.   OBSTETRICS AND GYNECOLOGY

Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density

(2012) Christian Muschitz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

(2012) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene

(2012) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Six Months of Parathyroid Hormone (1–84) Administered ConcurrentlyVersusSequentially with Monthly Ibandronate Over Two Years: The PTH and Ibandronate Combination Study (PICS) Randomized Trial

(2012) Anne L. Schafer et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy

(2011) Andrea Z. LaCroix   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

(2011) Matthew Austin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

(2010) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis

(2010) Joel S. Finkelstein et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis

(2010) J. J. Stepan et al.   OSTEOPOROSIS INTERNATIONAL

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

(2009) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin

(2008) Gerardo Heiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate

(2008) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

(2007) Steven Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM